** Retail pharmacy franchisor Sigma Healthcare's SIG.AX shares are considered overvalued by Morningstar despite in-line earnings
** Full-year underlying EBIT growth more than doubled to A$68 mln was within co's forecast - Brokerage
** Adds revenue surged 46% to A$4.8 bln, mainly due to increased prescription volumes supplied to Chemist Warehouse $(CW)$
** However, gross margins in H2 shrank more than anticipated to 5.4% due to lower-margin prescription medicine sales - Morningstar
** Brokerage adds that SIG's market cap is similar to grocer Woolworths WOW.AX at over A$34 bln, suggesting a P/E ratio of 42 for fiscal 2029, including earnings from CW indicating overvaluation
** Morningstar maintains A$1.65/share fair value estimate
** Stock up 11.1% YTD
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。